Subgroup analysis by baseline (BL) weight-associated parameters: A phase III study of liposomal irinotecan (nal-IRI)±-5fluorouracil/leucovorin (5-FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based (gem) therapy.

被引：0

作者：

Macarulla, Teresa Mercade

Hubner, Richard

Blanc, Jean-Frederic

Wang-Gillam, Andrea

Li, Chung-Pin

Bodoky, Gyorgy

Dean, Andrew Peter

Yanshen, Shan

Jameson, Gayle S.

Lee, Kyung-Hun

Chiu, Chang-Fang

Schwartsmann, Gilberto

Braiteh, Fadi S.

Cunningham, David

Chen, Li-Tzong

Von Hoff, Daniel D.

Mamlouk, Khalid Kevin

de Jong, Floris A.

Siveke, Jens T.

机构：

[1] Vall d Hebron Univ Hosp, Inst Oncol, Barcelona, Spain

[2] Christie NHS Fdn Trust, Manchester, Lancs, England

[3] CHU Bordeaux, Pole ADEN, Hop Haut Leveque, Bordeaux, France

[4] Washington Univ, Sch Med St Louis, St Louis, MO USA

[5] Taipei Vet Gen Hosp, Taipei, Taiwan

[6] Szent Laszlo Teaching Hosp, Budapest, Hungary

[7] St John God Hosp, Subiaco, WA, Australia

[8] Natl Cheng Kung Univ Hosp, Tainan, Taiwan

[9] Honor Hlth, Virginia G Piper Canc Ctr, Scottsdale, AZ USA

[10] Seoul Natl Univ Hosp, Seoul, South Korea

[11] China Med Univ First Hosp, Taichung, Taiwan

[12] Fed Univ, Porto Alegre, RS, Brazil

[13] Comprehens Canc Centers Nevada, Las Vegas, NV USA

[14] Royal Marsden NHS Fdn Trust, London, England

[15] Natl Hlth Res Inst, Natl Inst Canc Res, Tainan, Taiwan

[16] Ipsen Biosci Inc, Cambridge, MA USA

[17] Shire GmbH, Zug, Switzerland

[18] Univ Hosp Essen, West German Canc Ctr, Essen, Germany

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 04期

关键词：

D O I：

10.1200/JCO.2018.36.4_suppl.410

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

410

引用

页数：1